Hi Mark,

As I guess you might be expecting the answer is “It depends”.

1. It depends on your genotype
2. It depends on your budget
3. It depends on whether you want large scale trial evidence (Ledipasvir has higher numbers and more accurate statistics than Daclatasvir)

It’s an important decision and worth careful consideration. The problem at the moment is that Daclatasvir trial size is typically n=100 which gives an error range of +/- 10%. Even with Ledipasvir and trial sizes circa n=1000 the margin of error is still +/- 3% http://fixhepc.com/getting-treated/major-clinical-trials.html#margin-of-error.

The bottom line is that they both appear good, and both work for most of the people most of the time.